Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

14 May 2020Company News, Regulatory
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has received written comments from the U.S. Food and Drug Administration (FDA) in response to its End-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (“COPD”).

12 May 2020Regulatory
Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings

LONDON, May 12, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it has on May 7, 2020 granted to

1 May 2020Regulatory
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s potential across treatment settings and formulations LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Verona

30 April 2020Regulatory
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three months ended March 31, 2020, and provides a corporate update. Conference call today at 9:00 am EDT / 2:00 pm BST.

23 April 2020Regulatory
Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its financial results for the three months ended March 31, 2020 on Thursday, April 30, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results and provide a corporate update.

16 April 2020Regulatory
Result of AGM

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly approved by shareholders by way of a poll.

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2020. All rights reserved